•
AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure target discovered by BenevolentAI (AMS: BAI), a UK-based precision drug design company. This milestone achievement marks a significant step in their ongoing partnership, which was initially established in 2019 with a focus on idiopathic pulmonary…
•
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ: AZN), Bristol Myers Squibb (BMS; NYSE: BMY), and Takeda (NYSE: TAK). These partnerships underscore the biotech company’s commitment to leveraging its integrated AI and wet-lab technologies for the design of conformation- and target-selective antibody candidates.…
•
Subtle Medical Inc, a medical imaging specialist and Stanford University spin-off, has reportedly raised close to USD 10 million in a Series B+ financing round. The financing was backed by investors including Shanghai-based Wenzhou Capital, Fusion Fund, ENVISIONX Capital, Bluerun Ventures, and other strategic partners across the Asia Pacific region.…
•
This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France resulted in commitments to further open markets for foreign investors, particularly in the life sciences sector. President Xi emphasized the potential for increased trade and cooperation across several industries, specifically advocating for higher-value high-tech exports…
•
China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with compatriot firm invoX Pharma, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177). The collaboration aims to combine Insilico’s AI and computer-aided drug discovery expertise, including its proprietary PandaOmics target discovery engine, with invoX’s innovative drug…
•
Kingmed Diagnostics, a leading independent medical laboratory based in Guangdong, has entered into a strategic partnership with GenStar Biosolutions Co., Ltd, a Beijing-headquartered specialist in immune diagnostic technology. The collaboration aims to jointly develop auto-antibody immunofluorescence AI interpretation software and create an integrated, intelligent immunofluorescence detection platform. Financial details of…
•
Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost for key industries in the region. In the first quarter of 2024, a total of 420 major investment projects, each valued at over RMB 100 million (USD 13.8 million), were executed, culminating in a total…
•
AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic pulmonary fibrosis (IPF) candidate, tralokinumab, which has contributed to the development of Brainomix’s e-Lung software. This AI-enabled tool, announced by the UK medtech company this week, is designed to identify patients at risk of decline…
•
Shenzhen-based Edan Instruments Inc. has forged a strategic partnership with Global Health Labs Inc. to collaboratively develop an AI-driven, cost-effective handheld ultrasound device, leveraging their combined expertise and cutting-edge technology resources. This alliance aims to innovate handheld ultrasound technology by integrating artificial intelligence, making it accessible and affordable for grassroots…
•
The Centre for Artificial Intelligence and Robotics (CAIR), part of the Chinese Academy of Sciences (CAS) in Hong Kong, has officially launched CARES Copilot 1.0, a cutting-edge chatbot powered by a large language model designed to assist medical professionals in diagnosis and treatment. CARES Copilot 1.0 integrates the vast knowledge…
•
Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254), a Chinese pharmaceutical company, is venturing into a joint venture (JV) with Beijing-based AI-driven drug developer GigaCeuticals. The new JV, valued at RMB 120 million (USD 16.7 million), aims to collaborate on the research and development, industrialization, and commercialization of innovative drugs…
•
BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou Biopharmaceuticals Co., Ltd. The collaboration aims to harness their combined expertise in generative AI technology for target discovery, with the goal of developing IND-stage drugs and creating an advanced AIGC-driven antibody drug discovery platform. The…
•
US President Joe Biden last week issued an Executive Order titled “Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern,” which may present new challenges for China-based life science companies operating in the United States. The order is designed to curb the…
•
Baidu Health has entered into a partnership with Beijing-based pharmaceutical business service provider Souyao. The collaboration will capitalize on Baidu’s resource advantages in areas such as search engines, map navigation, health services, artificial intelligence (AI), and e-commerce to offer comprehensive technical and operational services for brick-and-mortar pharmacies. The goal is…
•
MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with Shanghai Henlius Biotech Inc. (HKG: 2696), a fellow Chinese firm, to co-develop AI-driven antibody drug conjugate (ADC) and anti-aging therapy platforms. This alliance combines Henlius’s comprehensive biopharmaceutical platform, specialized in antibody and Linker Payload technologies,…
•
Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered into a strategic partnership with the College of Radiology at Shandong First Medical University. The collaboration aims to encompass several key initiatives: The duo will jointly construct China’s inaugural “Medical Imaging Metaverse Immersive Teaching and…
•
Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to form a joint venture (JV) with MegaRobo Technologies, a Beijing-based firm renowned for its integration of robotics and artificial intelligence (AI) in life sciences. This strategic partnership aims to pioneer industry-standard medical laboratory automation solutions,…
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian company Variational AI to leverage the latter’s generative AI-powered model for drug discovery initiatives. Through this partnership, MSD will have early access to Variational AI’s platform, which utilizes text prompts to generate novel small molecules…
•
Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing in artificial intelligence (AI), quantum mechanics, and molecular simulation algorithms, have announced a strategic partnership agreement. This collaboration aims to revolutionize the drug discovery process by combining cutting-edge AI capabilities with advanced molecular dynamics simulation.…
•
Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with Huawei Cloud and Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) to develop “Healthy Little Beauty,” a health management artificial intelligence (AI) robot. This initiative marks the creation of China’s first AI robot…